Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration

Author： Doggrell Sheila A  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.6, Iss.8, 2005-07, pp. : 1421-1423

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pegaptanib sodium for the treatment of neovascular age-related macular degeneration

By Moshfeghi Andrew A   Puliafito Carmen A  

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 5, 2005-05 ,pp. : 671-682

Informa Healthcare

Access to resources Recommend Favorite

Pegaptanib: In Exudative Age-Related Macular Degeneration

By Siddiqui M. Asif A.   Keating Gillian M.  

Drugs, Vol. 65, Iss. 11, 2005-01 ,pp. : 1571-1577

Adis International

Access to resources Recommend Favorite

Pegaptanib of value for age-related macular degeneration

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 542, 2007-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

An update on the pharmacotherapy of neovascular age-related macular degeneration

By Freund K Bailey   Mrejen Sarah   Gallego-Pinazo Roberto  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 8, 2013-06 ,pp. : 1017-1028

Informa Healthcare

Access to resources Recommend Favorite

Neovascular Age-Related Macular Degeneration: Potential Therapies

By Chappelow Aimee V.   Kaiser Peter K.  

Drugs, Vol. 68, Iss. 8, 2008-01 ,pp. : 1029-1036

Adis International

Access to resources Recommend Favorite